a Fraction of patients that developed hypothyroidism and hyperthyroidism irAE across atezolizumab trials and their corresponding control arms. Low designates Common Terminology Criteria for Adverse Events (CTCAE) grading of 1 and 2. High designates CTCAE grade >2. b Left, results of an individual participant data (IPD) meta-analysis showing the 95% confidence intervals (CI) and point estimate for a time-dependent covariate in a Cox model associating occurrence of a given endocrine irAE and overall survival in patients treated with atezolizumab (N = 3552) or with standard of care treatments in the control arms (N = 2523) across 7 clinical trials from the safety evaluable population. IPD meta-analysis p-values for a two-sided Wald test that the logarithm (log) of the random effect estimate of a time-dependent covariate in a Cox model, stratified across trials, is non-zero for hypothyroidism p = 5.26 × 10−15, hyperthyroidism p = 1.02 × 10−4, type-1 diabetes p = 0.06, adrenal insufficiency p = 0.4, and hypophysitis p = 0.93 in atezolizumab treated patients. IPD meta-analysis p-values for patients in the control arms for hypothyroidism p = 0.0039, hyperthyroidism p = 0.03, type-1 diabetes p = 0.76, and adrenal insufficiency p = 0.29 obtained by the same test. Subpanels to the right show the 95% CI around the point estimate of the HR for this time-dependent covariate for hyperthyroidism and hypothyroidism split by each individual trial arm. Trials names are abbreviated as follows: imv211 = IMvigor211; impXXX = IMpowerXXX; imm151 = IMmotion151; impas130 = IMpassion130. Abbreviations for treatment combinations are coded as follows: Atezo = atezolizumab monotherapy; A = atezolizumab; C = carboplatin; P = paclitaxel; NabP = Nab-paclitaxel; B = bevacizumab; SUN = sunitinib; E = etoposide. Meta-analysis: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.